Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...

Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.

Boston Scientific shares trade at $91.87, down 16% from their 52-week high of $109.50, but analysts remain bullish. Thirty-three of 34 analysts rate the stock a buy, with a mean price target of ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Home ...

NMD Pharma is accelerating ignaseclant’s clinical development in CMT alongside multiple near-term clinical catalysts across its neuromuscular pipeline, with Phase 2 studies in spinal muscular atrophy ...

Novo Nordisk NVO announced positive top-line data from a late-stage study in its global REIMAGINE clinical study program for ...

Shares lower led by tech and banks; BHP overtakes CBA again for biggest stock; UBS now says RBA to hike again in May; bitcoin ...

As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.

CardioFocus, Inc., a medical device company dedicated to advancing pulsed field ablation (PFA) treatment for cardiac arrhythmias, announced major advancements across its PFA portfolio. OptiShot Unique ...

The diabetes and weight?loss drug market has entered 2026 with extraordinary momentum, building on the explosive growth seen throughout 2025. According to global health information technology ...